21 November 2023 false No description of principal activity Taxfiler 2024.6 true 15299935business:PrivateLimitedCompanyLtd2023-11-212024-12-31 152999352023-11-20 152999352023-11-212024-12-31 15299935business:AuditExemptWithAccountantsReport2023-11-212024-12-31 15299935business:FilletedAccounts2023-11-212024-12-31 152999352024-12-31 15299935business:Director12023-11-212024-12-31 15299935business:Director22023-11-212024-12-31 15299935business:RegisteredOffice2023-11-212024-12-31 15299935core:WithinOneYear2024-12-31 15299935core:ShareCapitalcore:PreviouslyStatedAmount2024-12-31 15299935core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-12-31 15299935core:PreviouslyStatedAmount2024-12-31 15299935business:SmallEntities2023-11-212024-12-31 15299935countries:EnglandWales2023-11-212024-12-31 15299935core:PlantMachinery2023-11-212024-12-31 15299935core:FurnitureFittings2023-11-212024-12-31 15299935core:PlantMachinery2023-11-20 15299935core:FurnitureFittings2023-11-20 15299935core:PlantMachinery2024-12-31 15299935core:FurnitureFittings2024-12-31 iso4217:GBP xbrli:pure
Company Registration No. 15299935 (England and Wales)
Future Medicine Limited Unaudited accounts for the period from 21 November 2023 to 31 December 2024
Future Medicine Limited Unaudited accounts Contents
Page
- 2 -
Future Medicine Limited Company Information for the period from 21 November 2023 to 31 December 2024
Directors
James Jean-Pierre Drake Danny Alexander Al-Khafaji
Company Number
15299935 (England and Wales)
Registered Office
Future Medicine Ltd 1 Albert Place London London N3 1QB England
- 3 -
Future Medicine Limited Statement of financial position as at 31 December 2024
2024 
Notes
£ 
Fixed assets
Tangible assets
2,318 
Current assets
Debtors
62,004 
Cash at bank and in hand
49,257 
111,261 
Creditors: amounts falling due within one year
(411,755)
Net current liabilities
(300,494)
Net liabilities
(298,176)
Capital and reserves
Called up share capital
100 
Profit and loss account
(298,276)
Shareholders' funds
(298,176)
For the period ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 5 August 2025 and were signed on its behalf by
Danny Alexander Al-Khafaji Director Company Registration No. 15299935
- 4 -
Future Medicine Limited Notes to the Accounts for the period from 21 November 2023 to 31 December 2024
1
Statutory information
Future Medicine Limited is a private company, limited by shares, registered in England and Wales, registration number 15299935. The registered office is Future Medicine Ltd, 1 Albert Place, London, London, N3 1QB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
25% Straight Line
Fixtures & fittings
25% Straight Line
Going concern
The accounts have been prepared on the going concern basis which assumes the continued support of Mr James Drake, who is a director of the company.
4
Tangible fixed assets
Plant & machinery 
Fixtures & fittings 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 21 November 2023
- 
- 
- 
Additions
1,608 
1,483 
3,091 
At 31 December 2024
1,608 
1,483 
3,091 
Depreciation
Charge for the period
402 
371 
773 
At 31 December 2024
402 
371 
773 
Net book value
At 31 December 2024
1,206 
1,112 
2,318 
- 5 -
Future Medicine Limited Notes to the Accounts for the period from 21 November 2023 to 31 December 2024
5
Debtors
2024 
£ 
Amounts falling due within one year
VAT
6,272 
Amounts due from group undertakings etc.
44,482 
Other debtors
11,250 
62,004 
6
Creditors: amounts falling due within one year
2024 
£ 
Trade creditors
25,470 
Taxes and social security
3,948 
Loans from directors
379,337 
Accruals
3,000 
411,755 
7
Transactions with related parties
Creditors as at 31 December 2024 include an amount of £379,337 payable to Mr James Drake who is a director of the company. Other debtors as at 31 December 2024 include amounts of £35,205 from Of Lost Time Limited and £9,277 from Drake Foundation, which is not-for profit company, where Mr James Drake is a director.
8
Average number of employees
During the period the average number of employees was 3.
- 6 -